Moleculin Biotech, Inc. (MBRX:NASDAQ) closed at $7.87 on November 13, 2026, down 2.36% on the day. The stock trades 96.6% below its 52-week high of $229.50 and 144.4% above its 52-week low of $3.22. Over the past year, it lost 27.5%. Moleculin Biotech, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 251 trading sessions since November 13, 2025, MBRX closed higher on 118 days (47%). Its best day was October 27, 2026 (+30.77%) and its worst was July 31, 2026 (-60.78%). The stock moved 10% or more in a single session 25 times.
Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
Find more stocks like MBRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.